Pharmacor Olmesartan Amlodipine 40/5 olmesartan medoxomil 40 mg / amlodipine (as besilate) 5 mg tablets bottle pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor olmesartan amlodipine 40/5 olmesartan medoxomil 40 mg / amlodipine (as besilate) 5 mg tablets bottle pack

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; silicified microcrystalline cellulose; stearic acid; pregelatinised maize starch; magnesium stearate; titanium dioxide; iron oxide yellow; purified talc; polyvinyl alcohol; macrogol 3350 - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

AKM Olmesartan Amlodipine 20/10 olmesartan medoxomil 20 mg / amlodipine (as besilate) 10 mg tablets blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

akm olmesartan amlodipine 20/10 olmesartan medoxomil 20 mg / amlodipine (as besilate) 10 mg tablets blister pack

pharmacor pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: silicified microcrystalline cellulose; stearic acid; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Pharmacor Olmesartan Amlodipine 40/5 olmesartan medoxomil 40 mg / amlodipine (as besilate) 5 mg tablets blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor olmesartan amlodipine 40/5 olmesartan medoxomil 40 mg / amlodipine (as besilate) 5 mg tablets blister pack

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: silicified microcrystalline cellulose; pregelatinised maize starch; stearic acid; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Pharmacor Olmesartan Amlodipine 20/5 olmesartan medoxomil 20 mg / amlodipine (as besilate) 5 mg tablets bottle pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor olmesartan amlodipine 20/5 olmesartan medoxomil 20 mg / amlodipine (as besilate) 5 mg tablets bottle pack

pharmacor pty ltd - olmesartan medoxomil, quantity: 20 mg; amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: silicified microcrystalline cellulose; stearic acid; pregelatinised maize starch; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Pharmacor Olmesartan Amlodipine 40/10 olmesartan medoxomil 40 mg / amlodipine (as besilate) 10 mg tablets bottle pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor olmesartan amlodipine 40/10 olmesartan medoxomil 40 mg / amlodipine (as besilate) 10 mg tablets bottle pack

pharmacor pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; stearic acid; pregelatinised maize starch; croscarmellose sodium; silicified microcrystalline cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

AKM Olmesartan Amlodipine 40/10 olmesartan medoxomil 40 mg / amlodipine (as besilate) 10 mg tablets blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

akm olmesartan amlodipine 40/10 olmesartan medoxomil 40 mg / amlodipine (as besilate) 10 mg tablets blister pack

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: stearic acid; pregelatinised maize starch; silicified microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

AKM Olmesartan Amlodipine 40/5 olmesartan medoxomil 40 mg / amlodipine (as besilate) 5 mg tablets bottle pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

akm olmesartan amlodipine 40/5 olmesartan medoxomil 40 mg / amlodipine (as besilate) 5 mg tablets bottle pack

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; stearic acid; silicified microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Pharmacor Olmesartan Amlodipine 20/5 olmesartan medoxomil 20 mg / amlodipine (as besilate) 5 mg tablets blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor olmesartan amlodipine 20/5 olmesartan medoxomil 20 mg / amlodipine (as besilate) 5 mg tablets blister pack

pharmacor pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: stearic acid; pregelatinised maize starch; magnesium stearate; croscarmellose sodium; silicified microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

MELOXAT 20 Milligram Film Coated Tablet Írland - enska - HPRA (Health Products Regulatory Authority)

meloxat 20 milligram film coated tablet

genthon bv - paroxetine mesylate - film coated tablet - 20 milligram

IMATINIB-TEVA imatinib 400 mg film-coated tablets blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

imatinib-teva imatinib 400 mg film-coated tablets blister pack

teva pharma australia pty ltd - imatinib mesilate, quantity: 477.877 mg (equivalent: imatinib, qty 400 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; magnesium stearate; purified water; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - 1) imatinib-teva (imatinib) is indicated for the treatment of patients with chronic myeloid leukaemia (cml). 2) imatinib-teva (imatinib) is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. 3) imatinib-teva (imatinib) is indicated for the treatment of adult patients with relapsed or refractory ph+all as monotherapy. 4) imatinib-teva (imatinib) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene rearrangements, where conventional therapies have failed. 5) imatinib-teva (imatinib) is indicated for the treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed. 6) imatinib-teva (imatinib) is indicated for the treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). 7) imatinib-teva (imatinib) is indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) 8) imatinib-teva (imatinib) is indicated for the adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist. 9) imatinib-teva (imatinib) is indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).